DDX11 and renal cell carcinoma: RCC cells transfected with DDX11 siRNA or control siRNA were treated with a clinically approved PARP inhibitor, olaparib; subsequently, immunofluorescence staining of PARP was performed to measure and investigate the increased PARP expression in nuclei of DDX11 knockdown RCC cells.